Adoptive transfer of membrane-restricted IL-12-TCR T cells promotes antigen spreading and elimination of antigen-negative tumor variants
Journal for ImmunoTherapy of Cancer · 2024-11 · 12 (11) · e009868
DOI: 10.1136/jitc-2024-009868 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 18.11.2024. Verfasst von Ling Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA zhangling@m…. Hauptthemen laut MEDLINE: Interleukin-12, Antigens, Neoplasm, Immunotherapy, Adoptive. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Intramural NIH HHS, Intramural Research Program of the National Institutes of Health.
Abstract (Originalsprache)
Background
Adoptive T-cell therapy has demonstrated clinical activity in B-cell malignancies, offering hope for its application to a broad spectrum of cancers. However, a significant portion of patients with solid tumors experience primary or secondary resistance to this treatment modality. Target antigen loss resulting either from non-uniform antigen expression or defects in antigen processing and presentation machinery is one well-characterized resistance mechanism. Constitutively expressed membrane-anchored interleukin-12 (caIL-12) has demonstrated enhanced antitumor activity and low systemic exposure in multiple preclinical adoptive T-cell treatment models with homogeneous tumor antigen expression. In this study, we assess the therapeutic impact of caIL-12 on target antigen-negative variants in syngeneic mouse models.
Methods
Target antigen-positive tumors were generated by transducing B16F10 melanoma cells (B16) or Lewis Lung Carcinoma cells (LLC) with a construct expressing the OVA antigen, SIINFEKL, tagged to ubiquitin (B16-U-OVA, LLC-U-OVA), while B16 or LLC tumors served as antigen-negative variants. C57BL/6J mice were subcutaneously injected with heterogeneous tumors composed of 80% B16-U-OVA and 20% B16. Bilateral tumors were established by injecting the left flank with B16-U-OVA or LLC-U-OVA tumors and the right flank injected with B16 or LLC tumors. The tumor-bearing mice then underwent 5.5 Gy total body irradiation, followed by adoptive transfer of OT-I TCR-T cells engineered with or without caIL-12.
Results
TCR-T cells (OT-I) delivered caIL-12 to the B16-U-OVA tumor sites and induced robust tumor control and survival benefits in mice bearing a heterogeneous tumor with OVA-negative variants. caIL-12 exerted its effect on OVA-negative B16 variants primarily by priming and activating endogenous antitumor CD8 T cells via antigen spreading. In addition, antigen spreading induced by OT-I-caIL-12 resulted in controlling OVA-negative tumors implanted at distant sites. This therapeutic effect required antigen-specific TCR-T cells and caIL-12 to colocalize at the tumor site, along with endogenous CD8 T cells capable of recognizing shared tumor antigens.
Conclusion
Expression of caIL-12 by tumor-targeting T cells demonstrated therapeutic effect against target-antigen-negative tumor variants, primarily through the induction of antigen spreading. These findings highlight the potential of caIL-12 to address challenges of antigen escape and tumor heterogeneity that may limit the efficacy of T-cell therapy against solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA zhangling@mail.nih.gov ch977@cinj.rutgers.edu.
- Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
- Department of Safety Assessment, Genentech Inc, South San Francisco, California, USA.
- Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
- CCR Collaborative Bioinformatics Resource (CCBR), Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
- Duncan and Nancy MacMillan Cancer Immunology and Metabolism Center of Excellence, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA zhangling@mail.nih.gov ch977@cinj.rutgers.edu.
ORCID-Profile: Ling Zhang, Scott M Norberg, John S Davies, Wiem Lassoued, James L Gulley
Förderung
- Intramural NIH HHS
- Intramural Research Program of the National Institutes of Health
Zitieren
APA
Zhang, L., Norberg, S. M., Karimipour, F., Davies, J. S., Kuznetsov, A., Lassoued, W., Burnett, D., Homan, P., Cam, M., Sinkoe, A., Xue, P., Gulley, J. L., & Hinrichs, C. S. (2024). Adoptive transfer of membrane-restricted IL-12-TCR T cells promotes antigen spreading and elimination of antigen-negative tumor variants. Journal for ImmunoTherapy of Cancer, 12(11), e009868. https://doi.org/10.1136/jitc-2024-009868
Vancouver
Zhang L, Norberg SM, Karimipour F, Davies JS, Kuznetsov A, Lassoued W, et al. Adoptive transfer of membrane-restricted IL-12-TCR T cells promotes antigen spreading and elimination of antigen-negative tumor variants. Journal for ImmunoTherapy of Cancer. 2024;12(11):e009868. doi:10.1136/jitc-2024-009868
BibTeX
@article{Zhang2024,
author = {Zhang, Ling and Norberg, Scott M and Karimipour, Farrah and Davies, John S and Kuznetsov, Alex and Lassoued, Wiem and Burnett, Daniel and Homan, Philip and Cam, Margaret and Sinkoe, Andrew and Xue, Ping and Gulley, James L and Hinrichs, Christian S},
title = {Adoptive transfer of membrane-restricted IL-12-TCR T cells promotes antigen spreading and elimination of antigen-negative tumor variants},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
volume = {12},
number = {11},
pages = {e009868},
doi = {10.1136/jitc-2024-009868}
}
EUVIMED